Departments and specialties
Mayo Clinic has one of the largest and most experienced practices in the United States,
with campuses in Arizona, Florida and Minnesota. Staff skilled in dozens of specialties work
together to ensure quality care and successful recovery.
Departments with related expertise
A laboratory technician prepares samples for testing.
Mayo Clinic researchers have a rich history in advancing precision medicine for breast cancer. Projects include:
- Finding new therapies for breast cancer
- Identifying an enzyme that regulates DNA repair
- Identifying subsets of women who do not benefit from cancer drugs called aromatase inhibitors
- Identifying genetic variations in the enzyme CYP2D6, which helps explain why some people with breast cancer don't respond to tamoxifen
- Developing a new drug to replace tamoxifen for people with low CYP2D6 enzyme activity
- Developing a new drug for women with resistance to aromatase inhibitors
- Identifying mechanisms for why some people do not respond to endocrine treatment, and then developing a new drug for breast cancer
See a list of publications by Mayo Clinic doctors on precision medicine for breast cancer on PubMed, a service of the National Library of Medicine.
Read more about breast cancer research laboratories and programs:
- Center for Individualized Medicine
- Breast Cancer SPORE
Precision medicine for breast cancer care at Mayo Clinic
May 18, 2018
- Alisertib with or without fulvestrant in treating patients with locally advanced or metastatic, endocrine-resistant breast cancer. https://clinicaltrials.gov/ct2/show/NCT02860000. Accessed Sept. 9, 2017.
- BRCA1 and BRCA2: Cancer risk and genetic testing. National Cancer Institute. http://www.cancer.gov/about-cancer/causes-prevention/genetics/brca-fact-sheet. Accessed June 13, 2017.
- Luo K, et al. A phosphorylation-deubiquitination cascade regulates the BRCA2-RAD51 axis in homologous recombination. Genes & Development. 2016;30:1.
- Van Poznak C, et al. Use of biomarkers to guide decisions on systemic therapy for women with metastatic breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Oncology Practice. 2015;11:514.
- Goetz MP (expert opinion). Mayo Clinic, Rochester, Minn. Sept. 26, 2017.
- Gradishar WJ, et al. Invasive breast cancer version 1.2016. Clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network. 2016;14:324.
- Studying genes. National Institute of General Medical Sciences. https://www.nigms.nih.gov/Education/pages/Factsheet_studyinggenes.aspx. Accessed June 13, 2017.
- AskMayoExpert. Genetic testing for BRCA1 and BRCA2 mutations. Rochester, Minn.: Mayo Foundation for Medical Education and Research; 2017.
- Mayo Clinic to be home of National Precision Medicine Initiative (PMI) Cohort Program Biobank. News release, Mayo Clinic, Rochester, Minnesota. Sept. 26, 2017.
- AskMayoExpert. Breast cancer. Rochester, Minn.: Mayo Foundation for Medical Education and Research; 2015.
- Goetz MP, et al. Tumor sequencing and patient-derived xenografts in the neoadjuvant treatment of breast cancer. Journal of the National Cancer Institute. 2017;109:djw306. Accessed June 12, 2017.
- Couch FJ, et al. Associations between cancer predisposition testing panel genes and breast cancer. JAMA Oncology. 2017;3:1190.
- Hamburg MA, et al. The path to personalized medicine. New England Journal of Medicine. 2010;363:301.
- Electronic Medical Records and Genomics (eMERGE) Network. National Human Genome Research Institute. https://www.genome.gov/27540473/electronic-medical-records-and-genomics-emerge-network/#al-2. Accessed June 12, 2017.
- Pritchard DE, et al. Strategies for integrating personalized medicine into healthcare practice. Personalized Medicine. 2017;14:141.
- The Personalized Medicine Coalition. Personalized Medicine at FDA: 2016 Progress Report. http://www.personalizedmedicinecoalition.org/Resources/Personalized_Medicine_at_FDA. Accessed June 13, 2017.
- Peshkin BN. Genetic counseling and testing for hereditary breast and ovarian cancer. http://www.uptodate.com/contents/search. Accessed June 13, 2017.
- Raby BA. Personalized medicine. https://www.uptodate.com/contents/search. Accessed June 13, 2017.
- Liu T, et al. CDK4/6-dependent activation of DUB3 regulates cancer metastasis through SNAIL1. Nature Communication. 2017;8:13923.
- Ingle JN, et al. Genetic polymorphisms in the long noncoding RNA MIR2052HG offer a pharmacogenomics basis for the response of breast cancer patients to aromatase inhibitor therapy. Cancer Research. 2016;76:7012.
- Ingle JN, et al. Estrogens and their precursors in postmenopausal women with early breast cancer receiving anastrozole. Steroids. 2015;99:32.
- Goetz MP, et al. CYP2D6 metabolism and patient outcome in the Austrian Breast and Colorectal Cancer Study Group trial (ABCSG) 8. Clinical Cancer Research. 2013;19:500.
- Goetz MP, et al. First-in-human phase I study of the tamoxifen metabolite Z-endoxifen in women with endocrine-refractory metastatic breast cancer. Journal of Clinical Oncology. In press. Accessed Oct. 17, 2017.
- D'Assoro AB, et al. The mitotic kinase Aurora-A promotes distant metastases by inducing epithelial-to-mesenchymal transition in Era(+) breast cancer cells. Oncogene. 2014;33:599.
Precision medicine for breast cancer